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Abstract 
Several studies have highlighted murine hematopoietic stem cell (HSC) heterogeneity using 
single cell transplantation, clonal tracking barcoding analysis as well as RNAseq single cell 
analysis. Here we have used data from a gene therapy trial to treat Wiskott-Aldrich syndrome 
(WAS) to explore hematopoiesis in humans. In the trial, the therapeutic vector (lentivirus) 
integrates into the genome at unique positions in each hematopoietic stem and progenitor cell 
(HSPCs) and is consequently transmitted to all its progeny. Thus hematopoietic ontogeny in 
humans can be inferred by tracking the appearance of unique integration sites in fractionated 
blood cell populations. We concentrated on four WAS patients treated by gene therapy with 
two distinct sources of autologous HSPC : bone marrow (BM) or mobilized peripheral blood 
(MPB) (following administration of granulocyte colony-stimulating factor (G-CSF)). In these 
patients, we have sorted peripheral blood samples for 5 cell types: myeloid (granulocytes and 
monocytes) and lymphoid subpopulations (T, B and NK cells), and analysed their IS profile 
(using our new optimized pipeline, INSPIIRED). Each IS corresponds to a particular 
stem/progenitor cell clone, for which we can quantify its contribution in each of the 5 
lineages. Using this approach, we have characterized up to tens of thousands IS per patients, 
including two timepoints of follow up (1 y and 3 y) in order to study longitudinal dynamic. 
Statistical methods to account for sparse sampling and imperfect cell purifications comprise 
an important part of our approach and are under development. In initial analysis, using 
clustering algorithms, we identified different groups of IS clones corresponding to different 
human hematopoietic differentiation programs. We showed that a significant fraction of IS 
clones are detected in a single lineage, while other IS clones are characterized by different 
levels of contribution to the myeloid and lymphoid lineages, highlighting the heterogeneity of 
human HSC. Clones contributing to all 5 lineages are readily recovered but this study also 
unravels a diversity of inferred hematopoietic programs with various potentials contributing 
to human blood homeostasis. Longitudinal analysis of clonal dynamics is ongoing, with 
preliminary results showing the maintenance of this heterogeneity of HSPC over time. We 
will also present the differences of hematopoietic programs observed between the two 
sources of HSPCs (BM or MPB). These new findings and approaches suggest the existence 
of various types of human HSPC and provide unique data on human hematopoiesis. 
 
